Stockscreener 앱 받기
10.04
1.93%
0.19
시간 외 거래:
10.00
-0.04
-0.40%
전일 마감가:
$9.85
열려 있는:
$9.85
하루 거래량:
616.94K
Relative Volume:
0.74
시가총액:
$532.24M
수익:
-
순이익/손실:
$-29.44M
주가수익비율:
-11.27
EPS:
-0.8906
순현금흐름:
$-24.66M
1주 성능:
+14.74%
1개월 성능:
+0.40%
6개월 성능:
+283.21%
1년 성능:
+497.62%
1일 변동 폭
$9.73
$10.16
1주일 범위
$8.69
$10.16
52주 변동 폭
$1.57
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
10.04 | 522.17M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | Morgan Stanley | Overweight |
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2026-02-09 | 개시 | Mizuho | Outperform |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma (IMMX) price target increased by 11.73% to 18.62 - MSN
Moving Averages: Should I trade or invest in Immix Biopharma IncWall Street Watch & Precise Swing Trade Alerts - baoquankhu1.vn
IMMX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bear Alert: Is Immix Biopharma Inc in a bullish channel2026 Analyst Calls & Weekly High Conviction Ideas - baoquankhu1.vn
Guidance Update: Is Immix Biopharma Inc stock a buy or sell2026 Bull vs Bear & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy - MSN
Immix Biopharma to Participate in Jefferies Global Healthcare Conference - National Today
Immix Biopharma to Host Investor Meetings at Jefferies Global Healthcare Conference 2026 - Quiver Quantitative
Immix Biopharma lines up investor meetings at Jefferies event - Stock Titan
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Bitget
Immix Biopharma (IMMX) seeks approval of board slate, auditor and reviews 2025 executive pay - Stock Titan
Earnings Recap: Is Immix Biopharma Inc benefiting from innovation trendsNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - stockinvest.us
Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation - MSN
IMMX PE Ratio & Valuation, Is IMMX Overvalued - Intellectia AI
Immix Biopharma ― NEXICART-2 の進展で勢いが増す - Smartkarma
Weekly Earnings: Is Immix Biopharma Inc stock a buy or sell2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Bear Alert: Is Immix Biopharma Inc benefiting from innovation trends2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Citizens reiterates Immix Biopharma stock rating on trial enrollment By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com
Immix Biopharma completes enrollment in AL amyloidosis trial By Investing.com - Investing.com South Africa
Immix Biopharma (IMMX) price target increased by 25.64% to 16.66 - MSN
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201 - tipranks.com
Immix completes enrollment in NEXICART-2; topline results expected Q3 2026 - TradingView
[8-K] Immix Biopharma, Inc. Reports Material Event - stocktitan.net
Immix Biopharma Completes Enrollment for Key AL Amyloidosis Trial - nationaltoday.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming Milestones - marketscreener.com
Immix Biopharma completes enrollment in AL amyloidosis trial - Investing.com
Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA). - Bitget
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - The Manila Times
Mizuho raises Immix Biopharma stock price target on cash position By Investing.com - Investing.com India
Mizuho raises Immix Biopharma stock price target on cash position - Investing.com
Should I trade or invest in Immix Biopharma Inc2026 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Immix Biopharma, Inc. 2025 Annual Report Amendment: Financial Statements, Auditor Correction, and Company Overview - Minichart
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) widens 2025 loss but ends year with $100M cash - stocktitan.net
Mizuho raises Immix Biopharma stock price target to $15 on cash position - Investing.com Australia
Mizuho raises Immix Biopharma stock price target to $15 on cash position By Investing.com - Investing.com South Africa
Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):